Xencor, Inc. (XNCR) Picks 400 mcg/kg RP3D for XmAb819; 45.5% cORR in ccRCC Cohort

Xencor, Inc. (XNCR) selected 400 mcg/kg IV as the proposed Phase 3 dose for XmAb819 after Phase 1 data showed 45.5% confirmed ORR and 82% 6-month PFS in ccRCC. A randomized trial vs tivozanib is planned, with potential registration-enabling study by end of 2027.

Original reporting
Published Oct 25, 2026, 8:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Xencor, Inc. (XNCR) Picks 400 mcg/kg RP3D for XmAb819; 45.5% cORR in ccRCC Cohort — source image
Decision brief

The 30-second read

$XNCRBullishMed
01

Why it matters

The dose selection and high response rates provide a tangible catalyst for the company's pipeline and may attract partnership interest.

02

Market read

First disclosure of Phase 3 dosing and strong early efficacy data; likely short‑term price move for XNCR.

03

What to watch

Regulatory timeline and potential competition from other ccRCC therapies could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Xencor is developing XmAb819, a solid‑tumor T‑cell engager targeting clear cell renal cell carcinoma.

Company-level read

Ticker impact

$XNCRBullishHigh confidence
Context

Xencor announced a Phase 3 dose of 400 mcg/kg for XmAb819 after Phase 1 data showed 45.5% ORR and 82% 6‑month PFS in a ccRCC cohort.

Expected impact

likely upward pressure as investors price in the promising efficacy signal.

Evidence & confidence

First disclosure of a concrete Phase 3 dose and strong response rates for a biotech micro‑cap typically triggers a short‑term rally.

Market effects

reinforces confidence in T‑cell engager platforms and may lift peer biotech valuations.

U.S. biotech sector sees modest uplift.

limited to biotech investors; no broad market effect.

Counterpoint

The data set is small (n=11) and early; investors may wait for larger Phase 2/3 results before committing.

Key entities

  • Xencor, Inc.

    Biotech firm developing T‑cell engager therapeutics.

  • XmAb819

    Investigational T‑cell engager for ccRCC.

Related articles

$XNCRMedAI 8/10

Xencor reports early trial data for autoimmune therapies

Xencor Inc. (XNCR) shared early Phase 1b trial data for plamotamab in rheumatoid arthritis patients, showing significant B-cell reduction and clinical improvements. The study reported adverse events like pyrexia and cytokine release syndrome. Xencor also updated on XmAb657, with plans to start trials in severe autoimmune diseases in Q1 2027.

$XNCRHighAI 8/10

Xencor Reports Third Quarter 2026 Financial Results

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xencor Reports Third Quarter 2026 Financial Results -- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO -- -- Early dose-escalation data fo

$XNCRHighAI 8/10

Truist raises Xencor stock price target on kidney cancer drug data

Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.